Bristol-Myers cancer immunotherapy advances on two fronts

July 20 (Reuters) - Bristol-Myers Squibb Co's Opdivo, a new oncology drug that makes cancer cells more susceptible to the immune system, on Monday won European approval to treat a form of lung cancer and was also found to be beneficial in patients with advanced kidney cancer.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.